Purple Biotech Ltd
purple-biotech.comWhat Do They Do?
Develops cancer drug candidates, including antibody therapies and a small-molecule drug, to treat patients with cancer.
20-F for FY2025, filed Mar 19, 2026We are a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while…View ↗
CAPTN-3: A platform of masked tri-specific antibodies that simultaneously target tumor-associated antigens while engaging both T cells and…View ↗
CM24: CM24, is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion…View ↗
NT219: A dual-inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and…View ↗
How Are They Changing?
A sharper platform focus
The older report described antibody and small-molecule candidates in active clinical studies alongside an early-stage tri-specific antibody; the latest centers on the tri-specific platform and makes further development of the earlier clinical assets contingent on partnering or investment.
20-F for FY2022, filed Mar 3, 2023 20-F for FY2025, filed Mar 19, 2026We are conducting a randomized, controlled, open label multicenter phase 2 study to investigate CM24 in combination with the anti-PD-1…View ↗
We are conducting a phase 1/2 dose escalation study of NT219 as a single agent in patients with solid tumors, and a dose escalation phase…View ↗
We are conducting preclinical studies with IM1240 and expect to reach IND submission in approximately two years.View ↗
We are a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while…View ↗
CM24: CM24, is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion…View ↗
NT219: A dual-inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and…View ↗
Loading...
